CN Patent

CN118767117A — 体内功效延长的生长激素

Assigned to Novo Nordisk Health Care AG · Expires 2024-10-15 · 2y expired

What this patent protects

本发明涉及具有功效延长特征的生长激素化合物。通过使白蛋白结合残基通过亲水间隔基与生长激素变体连接来获得这种效果。还描述了制备这类化合物和使用这类化合物的方法。这些生长激素化合物基于其改变的特征，认为所述特征特别可用于治疗。

USPTO Abstract

本发明涉及具有功效延长特征的生长激素化合物。通过使白蛋白结合残基通过亲水间隔基与生长激素变体连接来获得这种效果。还描述了制备这类化合物和使用这类化合物的方法。这些生长激素化合物基于其改变的特征，认为所述特征特别可用于治疗。

Drugs covered by this patent

Patent Metadata

Patent number
CN118767117A
Jurisdiction
CN
Classification
—
Expires
2024-10-15
Drug substance claim
No
Drug product claim
No
Assignee
Novo Nordisk Health Care AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.